These findings confirm the marked differences in the TP53 mutation and p53 expression rate across primary, metastatic castration-naïve, and castration-resistant PCa and suggests that TP53 alterations may be acquired early in disease progression and contribute to the development of lethal PCa. The gene discussed is TP53; the disease is posterior cortical atrophy.